middle.news
Arovella Secures $20M to Propel ALA-101 into Phase 1 Trials
10:57am on Friday 31st of January, 2025 AEDT
•
Biotechnology
Read Story
Arovella Secures $20M to Propel ALA-101 into Phase 1 Trials
10:57am on Friday 31st of January, 2025 AEDT
Key Points
Raised $20 million via placement at $0.17 per share
Pro-forma cash position of $30.6 million post-placement
Clinical Advisory Board formed with leading oncologists
Progressing FDA IND application for ALA-101 Phase 1 trial
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Arovella Therapeutics (ASX:ALA)
OPEN ARTICLE